What did @briannaashleyy actually say?
Brianna started semaglutide in early March at 155 pounds and is now sitting at 138, a loss of roughly 17 pounds over several months. She credits the early weight loss to a combination of "semaglutide, walking and being in a calorie deficit" and admits the past month or so she stopped tracking and just ate "in moderation." She plans to stop semaglutide after July to see if she can maintain on her own. She also mentions starting through a platform called Amble and reaching what she describes as her maximum allowed dose.
To her credit, she is not claiming semaglutide did all the work. She explicitly ties her early results to the full package: the drug, daily walking, and a calorie deficit. That kind of honesty is rarer than you'd think in GLP-1 content on TikTok.
Does the science back this up?
Yes, largely. The mechanism she is describing, appetite suppression enabling a sustained calorie deficit, is exactly how semaglutide produces weight loss. The drug does not burn fat directly. It slows gastric emptying and acts on GLP-1 receptors in the brain to reduce hunger signals.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that participants on 2.4mg semaglutide lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. However, that trial involved weekly injections at the full Wegovy dose with structured lifestyle support. Brianna lost roughly 11% of her starting weight, which tracks reasonably well with real-world outcomes, especially since she was not rigidly adherent the entire time.
Her observation that she lost most weight early and then plateaued as habits slipped also matches what the literature shows. Weight loss on semaglutide tends to be front-loaded, with diminishing returns over time (Davies et al., 2021, Lancet).
What did they get wrong (or right)?
She gets more right than wrong here. The attribution of results to a combination of drug plus behavior is accurate and important. Too many GLP-1 videos imply the medication alone does everything. It does not.
One thing worth flagging: she says "I'm not mad at it" while appearing to reference her weight as 130, but earlier she said she is currently at 138. That is a small inconsistency, likely just verbal slippage, but worth noting for anyone doing the math.
The bigger gap is her plan to just "cut herself off" cold after July. She does not mention any tapering plan or medical supervision for discontinuation. The STEP 4 trial (Rubino et al., 2021, JAMA) found that people who stopped semaglutide regained about two-thirds of their lost weight within a year without continued lifestyle intervention. Stopping without a plan is not dangerous, but her framing of it as a simple break undersells how real that regain risk is.
She also does not mention any side effects beyond early tiredness and nausea, which is fine as far as it goes, but the audience should know those are not the only possible effects.
What should you actually know?
Semaglutide is a prescription medication approved by the FDA for chronic weight management under the brand name Wegovy (2.4mg weekly) and for type 2 diabetes as Ozempic. It is not a permanent fix. The evidence is consistent on one point: stop the drug without maintaining behavioral changes and the weight tends to return.
Brianna's results sit within normal range for real-world use, but her trajectory also shows the drug working best when paired with structured habits, and results softening when those habits slip. That is not a knock on her. That is just how the drug works.
If you are considering semaglutide, the most important thing is not what dose you start at or how fast you lose weight. It is whether you have a plan for after, including how to maintain the appetite and behavioral changes the drug helped you build. A prescribing clinician should be part of that conversation, not just a TikTok comment section.
Bottom line
This is one of the more honest GLP-1 update videos you will find. Brianna does not overclaim the drug's role, she acknowledges inconsistency, and she is transparent about her actual numbers. The main thing missing is a realistic look at what stopping semaglutide without a maintenance plan typically leads to. That is not a small omission, but it does not make the rest of the video wrong.